Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -24.90% is 56% above its 5-year average of -57.22%, near the high end of its 5-year range (-107.88%–-16.55%).
As of the fiscal period ended Tuesday, June 30, 2026. 58.91% above its 12-month average of -60.59%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -24.90%.
RETURN ON EQUITY (ROE)
-24.90%
RETURN ON EQUITY (ROE) AVG TTM
-60.59%
RETURN ON EQUITY (ROE) AVG 3Y
-71.80%
RETURN ON EQUITY (ROE) AVG 5Y
-57.22%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+58.91%
CURRENT VS 3Y AVG
+65.32%
CURRENT VS 5Y AVG
+56.49%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+40.73%
vs the sector median at left
Shattuck Labs, Inc.
Market Cap
$529.58M
Return on Equity (ROE)
-24.90%
TTM Avg
-60.59%
3Y Avg
-71.80%
5Y Avg
-57.22%
Market Cap
$531.52M
Return on Equity (ROE)
-306.61%
TTM Avg
-169.61%
3Y Avg
-163.97%
5Y Avg
-73.13%
Market Cap
$531.98M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$533.04M
Return on Equity (ROE)
-13.64%
TTM Avg
-19.13%
3Y Avg
-73.22%
5Y Avg
-63.52%
Market Cap
$524.43M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$538.01M
Return on Equity (ROE)
N/A
TTM Avg
6.49%
3Y Avg
6.51%
5Y Avg
-75.00%
Market Cap
$519.25M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$516.76M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$548.51M
Return on Equity (ROE)
N/A
TTM Avg
91.17%
3Y Avg
180.92%
5Y Avg
76.31%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | $529.58M | -24.90% | -60.59% | -71.80% | -57.22% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | -306.61% | -169.61% | -163.97% | -73.13% |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 0.44% | -17.98% | 71.24% | -6.51% |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | -13.64% | -19.13% | -73.22% | -63.52% |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | -17.44% | -97.25% | -87.77% | -77.06% |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A | 6.49% | 6.51% | -75.00% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.35% | -58.07% | -51.86% | -46.32% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | -60.79% | -73.94% | -62.04% | -71.62% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A | 91.17% | 180.92% | 76.31% |
| 908 Devices Inc. (MASS)vs › | $505.87M | -27.20% | -44.25% | -32.03% | -24.61% |
ROE
-24.9%
ROA
-23.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -24.90% |
| 2026-03-31 | -52.04% |
| 2025-12-31 | -59.24% |
| 2025-09-30 | -58.87% |
| 2025-06-30 | -107.88% |
| 2025-03-31 | -104.47% |
| 2024-12-31 | -94.71% |
| 2024-09-30 | -77.06% |
| 2024-06-30 | -77.10% |
| 2024-03-31 | -66.05% |
| 2023-12-31 | -60.33% |
| 2023-09-30 | -84.25% |
| 2023-06-30 | -66.53% |
| 2023-03-31 | -62.25% |
| 2022-12-31 | -57.87% |
| 2022-09-30 | -34.44% |
| 2022-06-30 | -27.62% |
| 2022-03-31 | -23.17% |
| 2021-12-31 | -16.55% |
| 2021-09-30 | -24.82% |
| 2021-06-30 | -21.38% |
| 2021-03-31 | -14.02% |
| 2020-12-31 | -11.81% |
| 2020-06-30 | -23.02% |
| 2020-03-31 | -178.21% |
